Key facts
- It has raised $5.2M; the latest was Later Stage VC ($5.0M) in Nov 2025.
- Notable investors include Y Combinator, Centre for Cellular And Molecular Platforms, Enzia Ventures, HealthVenture, Inflexor — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Morphle
- ·The full record, as it builds
Funding rounds
No funding rounds for Morphle are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Morphle
Developer of an online pathology scanner designed to facilitate pathologists in collaborating with other doctors in real time. The company's scanner offers robotic plug-and-play whole slide scanners that provide high-resolution image quality, quick scanning, and image analysis tools, which are uploaded to the cloud, enabling pathologists to diagnose over a computer or tablet.
- Sector
- Healthcare
- HQ
- Lewes, DE, United States
- Founded
- 2017
- Employees
- 79
- Website
- morphlelabs.com/
- Ownership
- Privately Held (backing)
Morphle doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Morphle shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Morphle in its N-PORT filings yet. We sweep new filings monthly.